GC
ADMA icon

Grimes & Company’s ADMA Biologics ADMA Stock Holding History

Grimes & Company’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98.8K Hold
11,805
– – ﹤0.01% 443
2026
Q1 		$106K Sell
11,805
-1,642
-12% -$25.9K ﹤0.01% 425
2025
Q4 		$245K Sell
13,447
-227
-2% -$3.83K 0.01% 405
2025
Q3 		$200K Hold
13,674
– – ﹤0.01% 440
2025
Q2 		$249K Sell
13,674
-8,016
-37% -$163K 0.01% 365
2025
Q1 		$430K Sell
21,690
-1,122
-5% -$19.4K 0.01% 251
2024
Q4 		$391K Sell
22,812
-473
-2% -$8.9K 0.01% 277
2024
Q3 		$465K Sell
23,285
-16,702
-42% -$260K 0.01% 242
2024
Q2 		$447K Sell
39,987
-5,280
-12% -$44.3K 0.01% 231
2024
Q1 		$299K Hold
45,267
– – 0.01% 271
2023
Q4 		$205K Hold
45,267
– – 0.01% 303
2023
Q3 		$162K Hold
45,267
– – 0.01% 283
2023
Q2 		$167K Hold
45,267
– – 0.01% 288
2023
Q1 		$150K Sell
45,267
-8,047
-15% -$27.8K 0.01% 278
2022
Q4 		$207K Hold
53,314
– – 0.01% 267
2022
Q3 		$130K Hold
53,314
– – 0.01% 261
2022
Q2 		$106K Hold
53,314
– – 0.01% 266
2022
Q1 		$98K Sell
53,314
-872
-2% -$1.36K 0.01% 293
2021
Q4 		$76K Hold
54,186
– – ﹤0.01% 294
2021
Q3 		$61K Hold
54,186
– – ﹤0.01% 298
2021
Q2 		$87K Buy
54,186
+3,116
+6% +$5.48K ﹤0.01% 297
2021
Q1 		$90K Buy
51,070
+15,761
+45% +$36.1K ﹤0.01% 276
2020
Q4 		$69K Buy
35,309
+1,809
+5% +$3.8K ﹤0.01% 264
2020
Q3 		$80K Buy
+33,500
New +$91.9K 0.01% 244

Other funds holding ADMA

AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
MCM
Marathon Capital Management Hunt Valley, Maryland $494M AUM 42.6% 1-Year Est. Return
RL
Ruffer LLP London, United Kingdom $2.83B AUM 30.34% 1-Year Est. Return
PI
PFG Investments Woodbury, New York $2.58B AUM 36.93% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return

Grimes & Company's ADMA Position: Q2 2026 in Review

Grimes & Company held its ADMA Biologics (ADMA) position steady in Q2 2026 at 11,805 shares worth $98.8K. The position accounts for ﹤0.01% of the portfolio, ranked #443.

Grimes & Company first reported a position in ADMA in Q3 2020 and has held it in 24 quarters since. The position peaked at $465K in Q3 2024. 80 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Grimes & Company held 11,805 shares of ADMA Biologics worth $98.8K as of Q2 2026.
  • Grimes & Company left its ADMA Biologics share count unchanged in Q2 2026.
  • ADMA Biologics made up ﹤0.01% of Grimes & Company's portfolio in Q2 2026, its #443 holding.
  • Grimes & Company first reported a position in ADMA Biologics in Q3 2020 and has held it in 24 quarters since.
  • Grimes & Company's ADMA Biologics position peaked at $465K in Q3 2024.
  • 80 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.